No Data
No Data
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
China Securities Co., Ltd. recommends buying Aier Eye Hospital Group (06855) for the first time, citing the potential for continued high growth in revenue driven by the heavyweight BIC product.
China Securities Co., Ltd. released research reports stating that on June 14, 2024, Yasheng Pharmaceuticals (06855) announced that it had signed an exclusive option agreement with Takeda for its third-generation BCR-ABL inhibitor, orelabatib, granting Takeda global rights and licenses to orelabatib outside of China and some other regions. After the agreement is signed, the company will receive a $0.1 billion option fee and may be eligible for up to $1.2 billion in option exercise fees and additional potential milestone payments. Currently, the company has 16 FDA-approved new drugs in development and 1 in Europe.
Hong Kong stocks surge | Ascentage Pharma-B (06855) rose more than 4% in the morning, and Narita Knock won approval for listing in Macau. Previously received a payment of $100 million for Takeda's option payment.
Zhī tōng Cái jīng APP learned that Ascent Med-B (06855) jumped more than 4% in early trading, rising 3.4% to HK$28.9 as of the time of writing, with a turnover of HK$20.7353 million. On July 8th, Ascent Med announced that its core product, the third-generation BCR-ABL inhibitor, Olveretinib, was officially approved for listing in Macau, China. The group said that Olveretinib received special support from the national "Major New Drug Creation" project and is the first third-generation BCR-ABL inhibitor approved for listing by the National Medical Products Administration. The commercial promotion of Olveretinib in China is jointly undertaken by Ascent Med and Innovent Bio.
Multiple bullish factors continue to ferment, and the valuation of Asiapharm-B (06855) can be expected to increase.
With the increasing commercial value of global Osimertinib, the company's corresponding valuation is less than 10 billion Hong Kong dollars, in a significantly undervalued state, with expected future value realization.
Express News | Olverembatinib Approved for Commercialization in Macau China
Ascentage Grants Takeda Exclusive Option for Licensing of Blood Cancer Drug
No Data